Treatment of Non-falciparum Malaria

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Schweitzer Hospital
• Treatments: Artemether; Artemether-lumefantrine combination; Artemether, Lumefantrine Drug Combination; Artemisinins; Lumefantrine

Criteria

Inclusion Criteria:

• Male or female patients between the age of 6 months and 60 years and with a minimum of 5kg bodyweight

• Presence of uncomplicated malaria confirmed by: i)fever or history of fever in the previous 4 days, and ii)positive microscopy of P. malariae or P. ovale or mixed infection with P.falciparum with parasite density > 50-200000/μl of blood

• Written informed consent

Exclusion Criteria:

• Patients with presence of other clinical conditions requiring hospitalization

• Presence of other febrile conditions

• Presence of significant anemia, defined by hemoglobin < 7g/dl

• Known history of hypersensitivity,allergic or adverse reactions to artemether or lumefantrine

• Intake of any antimalarial or antibiotics with known antimalarial activity in the preceding 2 weeks

• Pregnant and breast feeding females